Brief: Santhera: Proposes Melanie Rolli As An Independent Director
March 27 (Reuters) - Santhera Pharmaceuticals Holding AG SANN.S: SANTHERA PHARMACEUTICALS (SIX: SANN) PROPOSES TO ELECT DR. MELANIE ROLLI AS AN INDEPENDENT DIRECTOR CURRENT BOARD MEMBER DR. OTTO SCHWARZ WILL NOT STAND FOR RE-ELECTION Further company coverage: SANN.S (Reporting by Berlin Newsroom) ((berlin.newsroom@thomsonreuters.com;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million